Designing the Next Generation of Alzheimer’s Disease Trials

Connect with Our Experts

Recent approvals of Alzheimer’s therapies represent a shift toward disease modification—but they also raise the stakes for trial design, early detection, and operational execution. Future success in Alzheimer’s Disease (AD) research depends on adapting to these changes with precision and foresight.

Our experts will guide you toward success. We can help you:

  • Adapt to a Changing AD Landscape: Align your strategy with the evolving treatment and regulatory environment.
  • Detect Disease Earlier: Leverage effective diagnostic methods to identify and enroll preclinical and early-stage patients.
  • Design with Confidence: Incorporate proven strategies from past AD trials—both symptomatic and disease-modifying—to reduce risk and improve outcomes.
  • Navigate Enrollment Complexity: Address challenges in identifying and recruiting preclinical patients for AD trials.

Meet Our Experts:


Andreas Schreiner, M.D. – Senior Vice President, Medical Affairs, Neuroscience & Analgesia
Chris Foster, PhD – Senior Project Manager, Neuroscience

Ready to get started?

Complete the form to have your development questions answered by our experts. 

Schedule A Meeting

By submitting your information to us through this webform, your business details will be added to our database. In accordance with our Privacy Notice, we may then contact you with marketing information about Premier Research that might be of interest to you. We will never sell your details to third parties. You can unsubscribe from marketing communications at any time.